PARIS — A 5-year interim analysis of the PERCEIVE real-world study showed sustained improvement of light sensitivity in patients treated with voretigene neparvovec.
“This is the biggest real-world analysis of voretigene neparvovec,” Dominik Fischer, MD, said at the Euretina congress. “It’s the post-approval registry that captures all patients outside the U.S.”
The primary objective of PERCEIVE was to characterize the long-term safety profile of Luxturna (voretigene neparvovec-rzyl, Spark Therapeutics) via systematic collection of adverse events of special interest and serious adverse events in